Enovis Announces Business Segment Leadership Transition Plan
05 Diciembre 2023 - 5:00AM
Enovis Corporation (NYSE: ENOV), an innovation-driven medical
technology growth company, today announced that Brady R. Shirley,
the Company’s President and COO, has informed the Company’s Board
of Directors of his plans to retire at the end of Q1 2025.
Brady will step down from his current position as President and COO
on April 1, 2024, and assume the role of Executive Advisor,
continuing to focus on the successful integration of the pending
Lima acquisition, innovation, and mentorship of Enovis business
leaders. Mr. Shirley’s transition to retirement at the end of the
first quarter 2025 will be thoughtfully managed with ample time for
overlap with other relevant executives within the organization. He
will remain a member of the Company’s Board of Directors.
The Company also announced that effective
January 2, 2024, Louie Vogt and Terry Ross will become executive
officers of the Company reporting to Enovis Chair and CEO, Matt
Trerotola.
-
Louie Vogt, president and general manager of surgical, has been
promoted to Group President Reconstructive (Recon), a newly created
role in which he will lead the Company’s global reconstructive
business segment.
- Terry Ross, president of bracing and supports, has been
promoted to Group President Prevention and Recovery (P&R), a
newly created role in which he will lead the Company’s global
P&R business segment.
Mr. Trerotola stated, “Brady has been recognized
as one of the most knowledgeable and inspirational leaders in the
orthopedics industry over the course of his 30-plus year career.
Since joining Enovis following our acquisition of DJO in 2019, he
has played an instrumental role in shaping our transition to a
focused medical technology company and leading our Recon growth
strategy. We look forward to his continued guidance and
counsel as he begins his transition to retirement, and we will
continue to benefit from his valuable contributions as a member of
our Board of Directors.”
Mr. Trerotola continued, “I want to congratulate
Louie and Terry on their upcoming promotions. Louie has a
proven track record driving double-digit growth and market
outperformance in our U.S. surgical business through innovation and
commercial excellence. Terry has played a vital role in the return
of our P&R segment to consistent growth and strong cash flow.
Louie and Terry are both exceptional leaders who play key roles in
developing talent, improving operating performance and margins, and
championing EGX processes and initiatives. We look forward to their
continued contributions in their new roles. This structure
gives us a unique opportunity to have Brady focus primarily on Lima
integration success while both he and I mentor Louie and Terry as
they step into these new roles.”
Mr. Ross joined Enovis (then known as Colfax) in
2012 as GM of Colfax Reliability Services and has held numerous
leadership roles, including Investor Relations, Strategy &
Business Development, and President of the Company’s Recovery
Sciences and Bracing and Support Businesses. Prior to joining
the Company, he served in management roles at Danaher and GE.
Mr. Vogt joined DJO (now Enovis) in 2017,
leading the Surgical Global Product Management and US Sales
Organizations before becoming President of the Enovis U.S. surgical
business. Prior to joining the Company, he spent 15 years with
Zimmer and Zimmer Biomet in a series of U.S. and Global Marketing,
Product Management and Commercial leadership roles.
About Enovis
Enovis Corporation (NYSE: ENOV) is an
innovation-driven medical technology growth company dedicated to
developing clinically differentiated solutions that generate
measurably better patient outcomes and transform workflows. Powered
by a culture of continuous improvement, global talent and
innovation, the Company’s extensive range of products, services and
integrated technologies fuels active lifestyles in orthopedics and
beyond. For more information about Enovis, please visit
www.enovis.com.
Forward-Looking Statements
This press release includes forward-looking statements,
including forward-looking statements within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include, but are not limited to,
statements concerning Enovis’ plans, goals, objectives, outlook,
expectations and intentions, and other statements that are not
historical or current fact. Forward-looking statements are based on
Enovis’ current expectations and involve risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied in such forward-looking statements. Factors
that could cause Enovis’ results to differ materially from current
expectations include, but are not limited to, the risks and other
factors detailed in Enovis’ reports filed with the U.S. Securities
and Exchange Commission (the “SEC”), including its most recent
Annual Report on Form 10-K and subsequent Quarterly Reports on Form
10-Q under the caption “Risk Factors,” as well as the other risks
discussed in Enovis’ filings with the SEC. In addition, these
statements are based on assumptions that are subject to change.
This press release speaks only as of the date hereof. Enovis
disclaims any duty to update the information herein.
Contact:
Kyle Rose Vice President, Investor Relations Enovis Corporation
+1-917-734-7450 investorrelations@enovis.com
Enovis (NYSE:ENOV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Enovis (NYSE:ENOV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024